106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2022 All rights reserved
ASCOBIO01224b
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve
cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/breast-cancer-guidelines.
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
breast-cancer-guidelines. Copyright © 2022 by American Society of Clinical Oncolog y. All rights
reserved.
Source
Fabrice A, Ismaila N, Allison KH, et al. Biomarkers for Adjuvant Endocrine and
Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol.
2022 April 19. doi: 10.1200/JCO.22.00069.
Abbreviations
AI, aromatase inhibitor; BCI, Breast Cancer Index; CTC, circulating tumor cells;
ctDNA, circulating tumor DNA; CTS5, Clinical Treatment Score post-5 years;
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC4,
immunohistochemistry 4; NEG, negative; POS, positive; PR, progesterone receptor;
RS, recurrence score; TILs, tumor-infiltrating lymphocytes; TN, triple negative;
TNBC, triple-negative breast cancer
